Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Salma Jabbour, Clinical Chief, Radiation Oncology and Vice Chair of Clinical Research & Faculty Development at RWJUH/Rutgers Cancer Institute. Together they discuss a plenary presentation that was given at ASCO 2023 on rectal cancer titled, the PROSPECT (Preoperative Radiation or Selective Preoperative Radiation and Evaluation before Chemotherapy and TME) trial.

The PROSPECT trial attempts to challenge the current treatment paradigm by individualizing treatment through the use of radiotherapy selectively rather than reflexively. This is a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for the treatment of locally advanced rectal cancer (LARC).

For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Soma Sengupta, the Harold C. Schott Endowed Brain Tumor Molecular Therapeutics Chair and Associate Professor of Clinical
at the University of Cincinnati. Together they explore the myriad of challenges in accurately diagnosing this aggressive brain tumor while examining the latest advancements in frontline treatment strategies.

For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Stephen Liu, Associate Professor of Medicine at Georgetown University and Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. Together they discuss the updated results of the ADAURA Trial presented at this year's ASCO meeting which demonstrated the overall survival benefit when adding osimertinib versus placebo in patients with completely resected stage IB-IIIA NSCLC, with/without adjuvant chemotherapy.

For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Giselle Sholler, Director of the Isabella Santos Rare and Solid Tumor Program at the Levine Children’s Hospital, and Professor of Pediatrics and Principal Investigator of the Sholler Pediatric Oncology Research Laboratory. Together they discuss trends in managing pediatric hematologic cancers and how molecular profiling and genomic profiling intersect with clinical care.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. JJ Gao, VP, Translational Informatics at Caris Life Sciences. Together they discuss his role in leading the Translational Informatics team at Caris Life Sciences and how artificial intelligence and bioinformatics is utilized to synthesize data to support cancer research and improve the outcomes of patients.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. R. Donald Harvey, Professor Department of Hematology and Medical Oncology at Emory University School of Medicine and Director of Winship Cancer Institute's Phase I Clinical Trials Unit. Together they discuss the role of the pharmacist in pharmacovigilance and pharmacoadherence, and how we can ensure that patients are being properly educated and compliant with the new products being approved each day.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Nate Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program and Vice Chair of Clinical Research for the Taussig Cancer Institute. Together they discuss the methodology and results of a recent JCO paper for which Dr. Pennell was a senior author: Modeling Costs and Life-Years Gained by Population-Wide NGS or Single-Gene Testing in Nonsquamous Non–Small-Cell Lung Cancer in the US.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Premal Thaker, Professor of Obstetrics and Gynecology, and Director of Gynecological Oncology Clinical Research at the Washington University School of Medicine in Saint Louis. Together they discuss the advances in gynecological malignancies in the era of precision medicine, how they have impacted her practice, and how HRD (homologous recombination deficiency) is changing the way we treat patients today.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Kristen Spencer, Assistant Professor, Department of Medicine and Director, Phase I Developmental Therapeutics Program at NYU Langone Perlmutter Cancer Center to discuss the latest findings and top abstracts presented at this year's ASCO GI meeting.

For more information, please visit: www.CarisLifeSciences.com

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down for an intimate discussion with Tiffany McConathy, nurse practitioner at Genesis Cancer and Blood Institute. Tiffany shares her family’s personal hardship of learning their eleven-month-old daughter Nora was diagnosed with embryonal tumor with multilayer rosettes (EMTR), a rare and untreatable form of pediatric brain cancer. Together, Chadi and Tiffany discuss Nora’s initial diagnosis, patient journey and the critical importance of dedicating research and resources to rare diseases such as EMTR.

For more information, please visit: www.CarisLifeSciences.com